Phase 1 and preclinical studies reveal safety, pharmacokinetics, and efficacy of intranasal delivery of the influenza antibody CR9114

Journal:

Science Translational Medicine

Published:

2026-02-04

DOI:

10.1126/scitranslmed.adz1580

Affiliations:

8

Authors:

21

Go to article

Institutions	Authors	Share
Leyden Laboratories, Netherlands	13.333333 13.333333	0.63
Beth Israel Deaconess Medical Center (BIDMC), United States of America (USA)	4.000000	0.19
Harvard University Health Services (HUHS), United States of America (USA)	1.166667	0.06
University of Kent, United Kingdom (UK)	0.833333	0.04
University of Greenwich, United Kingdom (UK)	0.833333	0.04
Ragon Institute of MGH, MIT and Harvard, United States of America (USA)	0.500000	0.02
The University of Sheffield, United Kingdom (UK)	0.333333	0.02

Interested in Immunology?